Transgenic overexpression of PKCε in the mouse prostate induces preneoplastic lesions

Cell Cycle

Volumn 10, Issue 2, 2011, Pages 268-277

  Benavides, Fernando ^a   Blando, Jorge ^b   Perez, Carlos J ^a   Garg, Rachana ^c   Conti, Claudio J ^a   DiGiovanni, John ^b   Kazanietz, Marcelo G ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Akt; Cell survival; PKC ; Preneoplastic lesions; Prostate; Transgenic mice

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROBASIN; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; PROTEIN S6; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL IMMORTALIZATION; CONTROLLED STUDY; GENE OVEREXPRESSION; MALE; MOUSE; NONHUMAN; PRECANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TRANSGENE;

MUS; MUS MUSCULUS; RATTUS;

EID: 79551571444     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.2.14469     Document Type: Article

References (50)

1. Newton AC. Regulation of protein kinase C. Curr Opin Cell Biol 1997; 9:161-7; PMID: 9069266; DOI:10.1016/S0955-0674(97)80058-0.
2. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007; 7:281-94; PMID: 17384583; DOI:10.1038/nrc2110.
3. Mischak H, Goodnight JA, Kolch W, Martiny-Baron G, Schaechtle C, Kazanietz MG, et al. Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence and tumorigenicity. J Biol Chem 1993; 268:6090-6; PMID: 8454583.
4. Cacace AM, Ueffing M, Philipp A, Han EK, Kolch W, Weinstein IB. PKCepsilon functions as an oncogene by enhancing activation of the Raf kinase. Oncogene 1996; 13:2517-26; PMID: 9000126.
5. Basu A, Sivaprasad U. Protein kinase Cepsilon makes the life and death decision. Cell Signal 2007; 19:1633-42; PMID: 17537614; DOI: 10.1016/j.cellsig. 2007.04.008.
6. Lu Z, Hornia A, Jiang YW, Zang Q, Ohno S, Foster DA. Tumor promotion by depleting cells of protein kinase Cdelta. Mol Cell Biol 1997; 17:3418-28; PMID: 9154841.
7. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 2003; 278:33753-62; PMID: 12824193; DOI: 10.1074/jbc.M303313200.
8. Garcia-Bermejo ML, Leskow FC, Fujii T, Wang Q, Blumberg PM, Ohba M, et al. Diacylglycerol (DAG)-lactones, a new class of protein kinase C (PKC) agonists, induce apoptosis in LNCaP prostate cancer cells by selective activation of PKCalpha. J Biol Chem 2002; 277:645-55; PMID: 11584014; DOI: 10.1074/jbc.M107639200.
9. Gorin MA, Pan Q. Protein kinase Cepsilon: an oncogene and emerging tumor biomarker. Mol Cancer 2009; 19:8-9; PMID: 19228372; DOI: 10.1186/1476-4598-8-9.
10. Pan Q, Bao LW, Kleer CG, Sabel MS, Griffith KA, Teknos TN, et al. Protein kinase Cepsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Research 2005; 65:8366-71; PMID: 16166314; DOI: 10.1158/0008-5472.CAN-05-0553.
11. Bae KM, Wang H, Jiang G, Chen MG, Lu L, Xiao L. Protein kinase Cepsilon is overexpressed in primary human non-small cell lung cancers and functionally required for proliferation of non-small cell lung cancer cells in a p21/Cip1-dependent manner. Cancer Res 2007; 67:6053-63; PMID: 17616661; DOI: 10.1158/0008-5472.CAN-06-4037.
12. Cornford P, Evans J, Dodson A, Parsons K, Woolfenden A, Neoptolemos J, et al. Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol 1999; 154:137-44; PMID: 9916928.
13. Koren R, Ben Meir D, Langzam L, Dekel Y, Konichezky M, Baniel J, et al. Expression of protein kinase C isoenzymes in benign hyperplasia and carcinoma of prostate. Oncol Rep 2004; 11:321-6; PMID: 14719062.
14. Aziz MH, Manoharan HT, Church DR, Dreckschmidt NE, Zhong W, Oberley TD, et al. Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727 and regulates its constitutive activation in prostate cancer. Cancer Res 2007; 67:8828-38; PMID: 17875724; DOI: 10.1158/0008-5472.CAN-06-3350.
15. Meshki J, Caino MC, von Burstin VA, Griner EM, Kazanietz MG. Regulation of prostate cancer cell survival by protein kinase Cepsilon involves bad phosphorylation and modulation of the TNFalpha/JNK pathway J Biol Chem 2010; 285:26033-40; PMID: 20566643; DOI: 10.1074/jbc.M110.128371.
16. McJilton MA, Van Sikes C, Wescott GG, Wu D, Foreman TL, Gregory CW, et al. Protein kinase Cepsilon interacts with Bax and promotes survival of human prostate cancer cells. Oncogene 2003; 22:7958-68; PMID: 12970744; DOI:10.1038/sj.onc.1206795.
17. Wu D, Thakore CU, Wescott GG, McCubrey JA, Terrian DM. Integrin signaling protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene 2004; 23:8659-72; PMID: 15467757; DOI:10.1038/sj.onc.1207900.
18. Wu D, Foreman TL, Gregory CW, McJilton MA, Wescott GG, Ford OH, et al. Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer. Cancer Res 2002; 62:2423-9; PMID: 11956106.
19. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, et al. Cancer Res 2009; 69:2287-95; PMID: 19244118; DOI: 10.1158/0008-5472.CAN-08- 2894.
20. Powel CT, Brittis NJ, Stec D, Hug H, Heston WD, Fair WR. Persistent membrane translocation of protein kinase Calpha during 12-0- tetradecanoylphorbol- 13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ 1996; 7:419-28; PMID: 9052983.
21. Gavrielides MV, Frijhoff AF, Conti CJ, Kazanietz MG. Protein kinase C and prostate carcinogenesis: targeting the cell cycle and apoptotic mechanisms. Curr Drug Targets 2004; 5:431-43; PMID: 15216909.
22. Gonzalez-Guerrico AM, Meshki J, Xiao L, Benavides F, Conti CJ, Kazanietz MG. Molecular mechanisms of protein kinase C-induced apoptosis in prostate cancer cells. J Biochem Mol Biol 2005; 38:639-45; PMID: 16336777.
23. Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000; 141:4698-710; PMID: 11108285; DOI: 10.1210/en.141.12.4698.
24. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ, et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 2005; 102:1151-6; PMID: 15657128; DOI: 10.1073/pnas. 0408925102.
25. Webber MM, Quader ST, Kleinman HK, Bello- DeOcampo D, Storto PD, Bice G, et al. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate 2001; 47:1-13; PMID: 11304724.
26. Thiyagarajan S, Bhatia N, Reagan-Shaw S, Cozma D, Thomas-Tikhonenko A, Ahmad N, et al. Role of GLI2 transcription factor in growth and tumorigenicity of prostate cells. Cancer Res 2007; 67:10642-6; PMID: 18006803; DOI: 10.1158/0008-5472.CAN-07-2015.
27. Achanzar WE, Brambila EM, Diwan BA, Webber MM, Waalkes MP. Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. J Natl Cancer Inst 2002; 94:1888-91; PMID: 12488483; DOI: 10.1093/jnci/94.24.1888.
28. Reddig PJ, Dreckschmidt NE, Ahrens H, Simsiman R, Tseng CP, Zou J, et al. Transgenic mice overexpressing protein kinase Cdelta in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol- 13-acetate. Cancer Research 1999; 59:5710-8; PMID: 10582689.
29. Reddig PJ, Dreckschmidt NE, Zou J, Bourguignon SE, Oberley TD, Verma AK. Transgenic mice overexpressing protein kinase Cepsilon in their epidermis exhibit reduced papilloma burden but enhanced carcinoma formation after tumor promotion. Cancer Res 2000; 60:595-602; PMID: 10676642.
30. Wang HQ, Smart RC. Overexpression of protein kinase C-alpha in the epidermis of transgenic mice results in striking alterations in phorbol ester-induced inflammation and COX-2, MIP-2 and TNFalpha expression but not tumor promotion. J Cell Sci 1999; 112:3497-506; PMID: 10504298.
31. Zhong C, Saribekyan G, Liao CP, Cohen MB, Roy- Burman P. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Res 2006; 66:2188-94; PMID: 16489020; DOI: 10.1158/0008-5472.CAN-05-3440.
32. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM, et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 2002; 99:2884-9; PMID: 11854455; DOI: 10.1073/pnas.042688999.
33. Li Y, Podsypanina K, Liu X, Crane A, Tan LK, Parsons R, et al. Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol Biol 2001; 2:2; PMID: 11178110; DOI: 10.1186/1471-2199-2-2.
34. Doble BW, Ping P, Kardami E. The epsilon subtype of protein kinase C is required for cardiomyocyte connexin- 43 phosphorylation. Circ Res 2000; 86:293-301; PMID: 10679481.
35. Barandon L, Dufourcq P, Costet P, Moreau C, Allières C, Daret D, et al. Involvement of FrzA/sFRP-1 and the Wnt/frizzled pathway in ischemic preconditioning. Circ Res 2005; 96:1299-306; PMID: 15920021; DOI: 10.1161/01.RES.0000171895.06914.2c.
36. Pardo OE, Wellbrock C, Khanzada UK, Aubert M, Arozarena I, Davidson S, et al. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J 2006; 25:3078-88; PMID: 16810323; DOI: 10.1038/sj.emboj.7601198.
37. Zhang J, Baines CP, Zong C, Cardwell EM, Wang G, Vondriska TM, et al. Functional proteomic analysis of a three-tier PKCepsilon-Akt-eNOS signaling module in cardiac protection. Am J Physiol Heart Circ Physiol 2005; 288:954-61; PMID: 15528226; DOI: 10.1152/ajpheart.00756.2004.
38. Lu D, Huang J, Basu A. Protein kinase Cepsilon activates protein kinase B/Akt via DNA-PK to protect against tumor necrosis factor-alpha-induced cell death. J Biol Chem 2006; 281:22799-807; PMID: 16785234; DOI: 10.1074/jbc.M603390200.
39. Kim DJ, Chan KS, Sano S, Digiovanni J. Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol Carcinog 2007; 46:725-31; PMID: 17610223; DOI: 10.1002/mc.20342.
40. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809; PMID: 19851315; DOI:10.1038/nrc2734.
41. Tam L, McGlynn LM, Traynor P, Mukherjee R, Bartlett JM, Edwards J. Expression levels of the JAK/ STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 2007; 97:378-83; PMID: 17595657; DOI: 10.1038/sj.bjc.6603871.
42. Kampfer S, Windegger M, Hochholdinger F, Schwaiger W, Pestell RG, Baier G, et al. Protein Kinase C isoforms involved in the transcriptional activation of cyclin D1 by transforming Ha-Ras. J Biol Chem 2001; 276:42834-42; PMID: 11551901; DOI: 10.1074/jbc.M102047200.
43. Cacace AM, Ueffing M, Han EK, Marmè D, Weinstein IB. Overexpression of PKCepsilon in R6 fibroblasts causes increased production of active TGFbeta. J Cell Physiol 1998; 175:314-22; PMID: 9572476; DOI: 10.1002/(SICI)1097-4652(199806)175:3<314::AIDJCP9>3.0.CO;2-R.
44. Koyanagi T, Noguchi K, Ootani A, Inagaki K, Robbins RC, Mochly-Rosen D. Pharmacological inhibition of epsilon PKC suppresses chronic inflammation in murine cardiac transplantation model. J Mol Cell Cardiol 2007; 43:517-22; PMID: 17655859; DOI: 10.1016/j.tem.2008.10.002.
45. Churchill EN, Qvit N, Mochly-Rosen D. Rationally designed peptide regulators of protein kinase C. Trends Endocrinol Metab 2009; 20:25-33; PMID: 19056296; DOI:10.1016/j.tem.2008.10.002.
46. Newton PM, Messing RO. The substrates and binding partners of protein kinase Cepsilon. Biochem J 2010; 427:189-96; PMID: 20350291.
47. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994; 8:230-9; PMID: 8170479.
48. Rodriguez-Puebla ML, LaCava M, Miliani De Marval PL, Jorcano JL, Richie ER, Conti CJ. Cyclin D2 overexpression in transgenic mice induces thymic and epidermal hyperplasia whereas cyclin D3 expression results only in epidermal hyperplasia. Am J Pathol 2000; 157:1039-50; PMID: 10980142.
49. Sundberg JBD. Systematic Approach to Evaluation of Mouse Mutations. 2001 CRC Press, Boca Raton FL.
50. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, et al. Prostate pathology of genetically engineered mice: definitions and classification. The Consensus Report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004; 64:2270-305; PMID: 15026373; DOI: 10.1158/0008-5472.CAN-03-0946.